BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol

Reuters02-10

BRIEF-<a href="https://laohu8.com/S/AARD">Aardvark Therapeutics</a> Announces FDA Submission And Irb Approval Of Amended Trial Protocol

Feb 10 (Reuters) - Aardvark Therapeutics Inc AARD.O:

AARDVARK THERAPEUTICS ANNOUNCES FDA SUBMISSION AND IRB APPROVAL OF AMENDED TRIAL PROTOCOL FOR LEAD CANDIDATE ARD-101, EXPANDING ELIGIBILITY IN PHASE 3 STUDY OF PRADER-WILLI SYNDROME
AARDVARK THERAPEUTICS INC - HERO TRIAL ENROLLMENT ON TRACK TO REPORT DATA Q3 2026

Source text: ID:nGNXLTFtB

Further company coverage: AARD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610211276?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 23:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610211276","market":"fut","top_or_hot":-1,"title":"BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> Announces FDA Submission And Irb Approval Of Amended Trial Protocol </title></head><body><p><span>Feb 10 (Reuters)</span><span> - </span>Aardvark <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>AARD.O</span>:</p><ul><li><p>AARDVARK THERAPEUTICS ANNOUNCES FDA SUBMISSION AND IRB APPROVAL OF AMENDED TRIAL PROTOCOL FOR LEAD CANDIDATE ARD-101, EXPANDING ELIGIBILITY IN PHASE 3 STUDY OF PRADER-WILLI SYNDROME</p></li><li><p>AARDVARK THERAPEUTICS INC - HERO TRIAL ENROLLMENT ON TRACK TO REPORT DATA Q3 2026</p></li></ul><p>Source text: <span>ID:nGNXLTFtB</span></p><p>Further company coverage: <span>AARD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> Announces FDA Submission And Irb Approval Of Amended Trial Protocol </title></head><body><p><span>Feb 10 (Reuters)</span><span> - </span>Aardvark <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>AARD.O</span>:</p><ul><li><p>AARDVARK THERAPEUTICS ANNOUNCES FDA SUBMISSION AND IRB APPROVAL OF AMENDED TRIAL PROTOCOL FOR LEAD CANDIDATE ARD-101, EXPANDING ELIGIBILITY IN PHASE 3 STUDY OF PRADER-WILLI SYNDROME</p></li><li><p>AARDVARK THERAPEUTICS INC - HERO TRIAL ENROLLMENT ON TRACK TO REPORT DATA Q3 2026</p></li></ul><p>Source text: <span>ID:nGNXLTFtB</span></p><p>Further company coverage: <span>AARD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AARD","symbol_name":"Aardvark Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUABV2FTH:1","article_id":"2610211276","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610211276","pubTimestamp":1770737342,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol Feb 10 (Reuters) - Aardvark Therapeutics Inc AARD.O:AARDVARK THERAPEUTICS ANNOUNCES FDA SUBMISSION AND I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AARD":"Aardvark Therapeutics"},"translate_title":"简介-Aardvark Therapeutics宣布FDA提交并获得Irb批准修订后的试验方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AARD":0.9},"content_text":"BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol Feb 10 (Reuters) - Aardvark Therapeutics Inc AARD.O:AARDVARK THERAPEUTICS ANNOUNCES FDA SUBMISSION AND IRB APPROVAL OF AMENDED TRIAL PROTOCOL FOR LEAD CANDIDATE ARD-101, EXPANDING ELIGIBILITY IN PHASE 3 STUDY OF PRADER-WILLI SYNDROMEAARDVARK THERAPEUTICS INC - HERO TRIAL ENROLLMENT ON TRACK TO REPORT DATA Q3 2026Source text: ID:nGNXLTFtBFurther company coverage: AARD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610211276","isCrawlerRequest":true}